Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration | MicrobiomeTrials← Back to trialsNCT02157077
Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
CompletedPHASE3INTERVENTIONAL
Trial Details
Start: 2013-12Est. Completion: 2015-12
Enrollment target: 84 participants Locations- Hôpital Pellegrin, Bordeaux, France
- Centre Hospitalier Intercommunal de Créteil, Créteil, France
- Hôpital général de Dijon, Dijon, France
- Centre d'Ophtalmologie Rabelais, Lyon, France
- Cabinet Alpes Rétine, Montbonnot-Saint-Martin, France
- CHR Hôtel Dieu, Nantes, France
- Centre d'explorations ophtalmologiques de l'odéon, Paris, France
- Hôpital des Quinze-Vingts, Paris, France
- Clinique Mathilde, Rouen, France
Other microbiome trials you might be interested in
Neovascular Age-related Macular Degeneration (nAMD)
This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, …
Santa Ana, United StatesEst. completion Oct 16, 2026
Geographic AtrophyMacular Degeneration
This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the…
Phoenix, United StatesEst. completion Oct 31, 2030